Skip to main content


Figure 2 | Thrombosis Journal

Figure 2

From: Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy

Figure 2

Hazard ratio and 95% CIs for major bleeding by statin use versus no statin use. Important subgroups of patients in the EINSTEIN DVT and PE studies. ASA, acetylsalicylic acid; BMI, body mass index; CI, confidence interval; CrCl, creatinine clearance; HR, hazard ratio; VKA, vitamin K antagonist; VTE, venous thromboembolism.

Back to article page